Original researchEffects of olanzapine alone and olanzapine/fluoxetine combination on health-related quality of life in patients with bipolar depression: Secondary analyses of a double-blind, placebo-controlled, randomized clinical trial
References (51)
- et al.
Health-related quality of life using the SF-36 in patients with bipolar disorder compared with patients with chronic back pain and the general population
J Affect Disord
(2000) - et al.
Improvement in health-related quality of life was associated with anti-depressive property: Evidence from an acute mania clinical trial of olanzapine versus divalproex
- et al.
- et al.
Differential changes in areas of social adjustment from depressive episodes through recovery
J Affect Disord
(1988) - et al.
A review of the health-related quality of life literature in bipolar disorder
Qual Life Res
(2001) - et al.
Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression
Arch Gen Psychiatry
(2003) - et al.
A comparative review of generic quality-of-life instruments
PharmacoEconomics
(2000) - et al.
Manic-Depressive Illness
(1990) - et al.
The long-term natural history of the weekly symptomatic status of bipolar I disorder
Arch Gen Psychiatry
(2002) - et al.
Bipolar affective disorder and substance abuse
J Clin Psychopharmacol
(1992)
Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study
JAMA
Is death from natural causes still exessive in psychiatric patients? A follow-up of 1593 patients with major affective disorder
J Nerv Ment Dis
Suicide attempts in bipolar patients
J Clin Psychiatry
Effectiveness and safety of long-term antidepressant treatment in bipolar disorder
J Clin Psychiatry
Rapid cycling in manic-depressives induced by tricyclic antidepressants
Arch Gen Psychiatry
Rapid cycling affective disorder: Contributing factors and treatment responses in 51 patients
Am J Psychiatry
Antidepressant-induced mania and cycle accelaration: A controversy revisited
Am J Psychiatry
Divalproex versus placebo for the treatment of bipolar depression
A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group
J Clin Psychiatry
A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group
J Clin Psychiatry
Practice guideline for the treatment of patients with bipolar disorder (revision)
Am J Psychiatry
Outcome in mania. A 4-year prospective follow-up of 75 patients utilizing survival analysis
Arch Gen Psychiatry
Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group
Am J Psychiatry
Efficacy of olanzapine in acute bipolar mania. A double-blind, placebo-controlled study. The Olanzapine HGGW Study Group
Arch Gen Psychiatry
Efficacy of olanzapine in acute bipolar mania. A double-blind, placebo-controlled study. The Olanzapine HGGW Study Group
Arch Gen Psychiatry
Olanzapine versus divalproex in the treatment of acute mania
Am J Psychiatry
Cited by (55)
Adjunctive antidepressants for the acute treatment of bipolar depression: A systematic review and meta-analysis
2022, Psychiatry ResearchCitation Excerpt :Fig. 1) Nineteen studies from 22 reports were included.( Altshuler et al., 2017; Amsterdam and Shults, 2005; AstraZeneca, 2012; Brown et al., 2009, 2006; Tufts Medical Center and NIMH, 2017; Chen et al., 2017; Keck et al., 2005; Nemeroff et al., 2001; Niu and Mu, 2013; Nolen et al., 2007; Pang, 2015; Qiu, 2013; Sachs et al., 2007; Schaffer et al., 2006; Shelton and Stahl, 2004; Shen et al., 2011; Shi et al., 2004; Tohen et al., 2003; Tu, 2012; Yatham et al., 2016) One was an abstract reported as an E-poster of the 26th European Congress of Psychiatry(Kostyukova et al., 2018), two were unpublished results of studies in ClinialTrials.gov,(AstraZeneca, 2012; Tufts Medical Center and NIMH, 2017) and six were from Chinese databases.( Chen et al., 2017; Niu and Mu, 2013; Pang, 2015; Qiu, 2013; Shen et al., 2011; Tu, 2012) (Table 1)
Effects of venlafaxine versus lithium monotherapy on quality of life in bipolar II major depressive disorder: Findings from a double-blind randomized controlled trial
2018, Psychiatry ResearchCitation Excerpt :In a review of the literature, Michalak et al. (2008) only identified 2 studies that tracked QoL outcomes in the treatment of bipolar depression. Using data from a sample of patients with bipolar I disorder, Shi et al. (2004) reported that the combination of olanzapine/fluoxetineproduced greater improvement in overall QoL ratings relative to placebo. Olanzapine monotherapy produced QoL changes that fell between those of the olanzapine/fluoxetine combination and placebo.
Differences in quality of life outcomes among depressed spinal cord injury trial participants
2015, Archives of Physical Medicine and RehabilitationOlanzapine plus fluoxetine for bipolar disorder: A systematic review and meta-analysis
2013, Journal of Affective DisordersReceptor targets for antidepressant therapy in bipolar disorder: An overview
2012, Journal of Affective DisordersCitation Excerpt :The same time the data are negative for paroxetine monotherapy (McElroy et al., 2010). Further analysis suggested that the OFC also improved many secondary indices (Shi et al., 2004) and could produce the beneficial effect already from day 7 (Dube et al., 2007). A small study (on 60 patients) without a placebo arm suggested that paroxetine and venlafaxine are equal, however this could be due to more drop outs in the venlafaxine group because of a higher switch rate, which balanced drop-outs in the paroxetine group due to lack of efficacy (Vieta et al., 2002).